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Abstract Only a limited number of economic evaluations
have addressed the costs and benefits of preconception care.
In order to persuade health care providers, payers, or pur-
chasers to become actively involved in promoting precon-
ception care, it is important to demonstrate the value of doing
so through development of a “business case”. Perceived ben-
efits in terms of organizational reputation and market share
can be influential in forming a business case. In addition, it is
standard to include an economic analysis of financial costs
and benefits from the perspective of the provider practice,
payer, or purchaser in a business case. The methods, data
needs, and other issues involved with preparing an economic
analysis of the likely financial return on investment in pre-
conception care are presented here. This is accompanied by
a review or case study of economic evaluations of precon-
ception care for women with recognized diabetes. Although
the data are not sufficient to draw firm conclusions, there
are indications that such care may yield positive financial
benefits to health care organizations through reduction in
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maternal and infant hospitalizations. More work is needed
to establish how costs and economic benefits are distributed
among different types of organizations. Also, the optimum
methods of delivering preconception care for women with
diabetes need to be evaluated. Similar assessments should
also be conducted for other forms of preconception care,
including comprehensive care.
Keywords Economic evaluation . Prenatal care .
Cost-benefit analysis . Diabetes in pregnancy . Birth defects
Introduction
The opportunity to assist a woman before she becomes
pregnant to improve her chances of a healthy pregnancy
is compelling. Adverse pregnancy outcomes, including birth
defects, preterm birth, and perinatal complications, are the
leading causes of infant mortality in the United States [1].
Further, developmental disabilities such as cerebral palsy re-
sult in direct and indirect economic costs that can exceed
$1 million over a given child’s lifetime [2], in addition to the
social and emotional costs incurred by families. A number
of additional conditions are associated with serious com-
plications of pregnancy, such as uncontrolled diabetes, hy-
pothyroidism, hypertension, use of alcohol or tobacco, and
obesity. The economic burden of most of these conditions in
conjunction with pregnancy has been poorly studied but is
likely to be enormous.
This paper discusses the potential economic benefits of
preconception care due to the prevention of adverse preg-
nancy outcomes with a focus on the data that would be
needed to assess costs and benefits. Currently, the needed
data and analyses are largely lacking. In the absence of in-
formation about the costs and benefits of comprehensive
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preconception care, which should ideally include nutritional
counseling, evaluation of medications, and family history
evaluation and genetic counseling, this paper focuses on prin-
ciples and methods. Three published studies have analyzed
the expected financial benefits from counseling women with
diabetes prior to pregnancy. These studies are compared and
lessons drawn, with discussion of implications of precon-
ception care for women with other conditions.
In order to argue that preconception care is a “good buy,”
its costs and benefits must be assessed from the perspectives
of a variety of stakeholders involved in health care services.
This paper will first define a “business case” analysis and out-
line the methods for determining the “return on investment”
from the perspective of various health care organizations.
Similarities and differences between such an analysis and
a standard cost-effectiveness analyses that calculate returns
to the health care system as a whole or to society will be
explained. Second, the paper reviews the literature on busi-
ness case analyses from areas other than preconception care.
Third, the paper discusses what data sources are available
and needed to apply business case methods in preconception
care with particular focus on women with diabetes. Finally,
the paper draws conclusions about future steps needed to
assess the business case for preconception care.
What is a business case analysis?
Concepts and definitions
A business case is an argument for a financial investment
couched in terms of potential economic or market advantages
to an organization, most commonly a private corporation [3].
The core of a business case is usually a budget impact analy-
sis, a calculation of the financial return on investment (ROI)
made by the firm(s) or organization(s) [4]. In addition to
financial returns, such as cost savings or cost avoidance, a
business case can be based on perceived strategic advantages
such as enhanced organizational reputation, market position-
ing, or increased employee and customer satisfaction. This
paper focuses just on financial business case analyses.
According to the Institute for Healthcare Improvement
(IHI) and the Commonwealth Fund [3]:
A business case for a health care improvement interven-
tion exists if the entity that invests in the intervention
realizes a financial return on its investment in a reason-
able time frame, using a reasonable rate of discounting.
This may be realized as “bankable dollars” (profit), a re-
duction in losses for a given program or population, or
avoided costs. In addition, a business case may exist if
the investing entity believes that a positive indirect effect
on organizational function and sustainability will accrue
within a reasonable time frame.
A business case related to health care is based on one or
several of the perspectives of specific payers, purchasers, or
providers. Because health care providers, payers, and pur-
chasers often have different, and sometimes conflicting, eco-
nomic incentives, the business case for the same interven-
tion will probably differ among these groups. For example,
improved ambulatory care may lead to reduced inpatient ad-
missions, which could result in financial savings for payers,
lost revenue for hospitals, and higher costs for ambulatory
care providers. The resulting misaligment of incentives in the
health care system may, and often does, lead to inappropriate
provision or use of certain services and underutilization of
others [3].
Although business case analyses by definition focus on
businesses, they are relevant to other stakeholders as well.
In particular, the consumer perspective is also important to
keep in mind. If consumers do not consider a service such
as preconception care to provide good value for their invest-
ment of time and money, low demand and utilization could
render the business case unfavorable. Further, government
agencies must meet budgets, and the short term financial im-
pact of policy changes may influence funding decisions. In
the long run, though, public health programs are expected
to optimize population health subject to resource availabil-
ity, which requires analysis of both short-term and long-term
health outcomes and economic consequences.
Analytical techniques and outcome measures
Financial analyses that underlie a business case are variably
referred to as budget impact and ROI analyses. It is important
to situate such analyses in the context of two commonly used
methods of economic evaluation, cost-effectiveness analysis
(CEA) and cost-benefit analysis (CBA) [5]. A CEA cal-
culates the net monetary cost per unit of health outcome
achieved. Certain preventive services are both more effective
than alternatives and less costly [6]. A CEA that yields ev-
idence of net cost savings from the payer perspective could
be used to frame a business case, but CEAs rarely report
payer-specific costs. In a CBA, all outcomes are expressed
in dollar values, and the summary measure is expressed as
either a net economic benefit or benefit-cost ratio. For exam-
ple, a CBA of prenatal care for undocumented immigrants
in California estimated that public funding cost the state $58
million but saved $211 million in long-term costs of care,
for a projected net benefit of $153 million and a benefit-cost
ratio of 4.6:1 [7].
A financial analysis of a business case can be viewed as
a CBA conducted from the perspective of an individual firm
or organization. One important distinction between finan-
cial analyses and standard economic evaluations is that the
latter are supposed to reflect the opportunity cost or value
of resources from a societal perspective whereas a financial
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analysis considers the direct monetary or budgetary impact
to a specific organization.
The ROI metric is typically calculated as the ratio of
dollars in increased revenue or decreased cost divided by
investment cost, although this can also be expressed as net
cost difference [8]. Various other metrics can be used in a
financial analysis, such as payback period or internal rate of
return. For example, a recent study estimated the number of
years that could be required for employers to realize a pos-
itive net benefit from bariatric surgery for obese employees
as a result of reduced medical costs (all of which were as-
sumed to be paid by the employer) and loss of work time [9].
ROI analyses require payer-specific costs, which are rarely
reported in standard CBA studies.
Time horizon and discount rate
Business case analyses generally employ a short time hori-
zon; for example, only changes in use and costs over a period
of 2 to 3 years following an intervention are typically con-
sidered. This reduces the problem of enrollee or employee
turnover. When individuals switch plans or employers, the
return on investments in the long-term health of that indi-
vidual made by the former health plan or employer will be
realized by someone else. This can make financial returns
to employers or health plans substantially lower than the
economic benefits to society [3, 10, 11]. A payback period
ranging from 5 years to 10 years [9] is not likely to be attrac-
tive to employers.
In economic evaluations from the societal perspective, it
is conventional to discount costs occurring in future years
using a discount rate of 3%, which reflects the social return
on capital [5]. For a business case analysis employing a short
time horizon, long-term future costs or benefits may not need
to be counted or discounted. In the short run, when ROI
analysis does employ discounting, the discount rate should
reflect the opportunity cost of capital in the private sector or
individual firm.
Prospective and retrospective evaluations
Financial and health economic analyses of an intervention
can be performed before or after its implementation. A
prospective analysis predicts the financial return for a new
initiative or program before it begins. This presumes that
there is reliable information about the effectiveness of the
intervention and accurate historical cost and revenue data.
Analysts construct a simulation model that projects likely
costs, health outcomes, and benefits based on a set of as-
sumptions. The benefits include anticipated savings in health
care costs and, for analyses from the employer perspective,
worker productivity [12, 13].
A limitation of prospective analyses is that key assump-
tions may turn out to be unrealistic. For example, analyses in
the 1980s and early 1990s projected cost savings to Medicaid
programs from reductions in the number of low birth weight
(LBW) births if prenatal care coverage were expanded (e.g.,
[14–16]). In conjunction with effective political advocacy
and policy changes, these arguments succeeded in more than
doubling the number of pregnancies covered by Medicaid
prenatal care between 1986 and 1991. Despite this expan-
sion, little or no reduction in LBW rates could be confirmed
to have occurred among eligible population groups [17]. The
lack of an observed effect may reflect deficiencies in the ef-
fectiveness of the routine prenatal care that was offered, as
well as barriers to access, and does not rule out a protective
effect of an optimal prenatal care protocol. Although prena-
tal care expansion had other health benefits and can easily
be defended, the cost-saving argument appears in retrospect
to have been overstated [18].
In the absence of information about intervention effec-
tiveness, a hypothetical calculation can be made regarding
the potential magnitude of benefits if an effective interven-
tion were to exist. One way to make such a calculation is
to take cost-of-illness estimates of the economic burden of
diseases and project the potential cost reduction that might
occur as a result of prevention. Only short-term costs, which
can be much smaller in magnitude than the long-term costs
included in cost-of-illness studies, are likely to be relevant to
employers or payers [19]. For example, one group of inves-
tigators calculated that poor birth outcomes such as preterm
birth cost employer-sponsored health plans $5.6 billion in
1990 and projected that prevention of 10% of preterm births
would lead to a cost savings of $560 million [20].
A retrospective or ex post analysis is based on observed
costs and benefits. For example, a recent ex post CBA of
folic acid fortification calculated that the economic returns
were substantially greater, and the costs somewhat lower,
than had been projected in previously published analyses
conducted prior to fortification [21]. Although actual data
can yield more reliable results, it is challenging to collect
data on multiple outcomes. Furthermore, interactions among
the outcomes or confounding of results from other sources
can make it difficult to precisely estimate the impact of the
initiative or program alone.
Lessons from business case literature
A number of business case studies of disease management
and health promotion initiatives have been published [8, 22,
23]. However, there is a paucity of well-conducted analyses
and studies that contain detailed data on intervention and
outcome costs [24]. Readers of business case analyses should
beware of publication bias [22] and “wish bias” leading to
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optimistic estimates of effectiveness and compliance with
behavioral changes [10].
One group that developed seven business case studies for
health care quality improvement initiatives, such as disease
management, concluded that health care providers, payers,
and purchasers cannot predictably expect to reap positive fi-
nancial returns from initiatives to improve health care quality
within short time horizons [3]. In the majority of case stud-
ies, short-term financial returns to health plan entities were
negative. Furthermore, returns to health care providers were
almost uniformly negative, as any cost savings were gener-
ally recouped by purchasers, and not by providers. In several
cases, managers felt that there was a business case for in-
vesting in improved quality based on organizational benefits
such as “retained market share, increased staff loyalty, and
reputation among employers” rather than cost savings [3].
Similarly, the Child Health Business Case Working Group
developed a set of business case studies [25]. For example,
a case study of postpartum screening for risk factors in new
mothers (e.g., depression, smoking, domestic violence) fol-
lowed by referral to community resources found that such
a program would lead to higher costs for the practice with-
out additional reimbursements. A positive business case for
providers may require a financial mechanism for tying reim-
bursements by payers to improved outcomes [3]. Integrated
health service providers under capitation payments may have
more opportunity to internalize the financial gains resulting
from improved care [3, 25].
Several studies reported positive financial returns to man-
aged care organizations (MCOs) from prenatal or perinatal
interventions targeted to high-risk pregnant women [26–29],
although these reports require validation and replication in
well-controlled studies. For example, a high-risk pregnancy
management program in upstate New York implemented by
a managed care program serving Medicaid and other lower-
income beneficiaries reported that cost savings from reduced
NICU (neonatal intensive care unit) admissions were more
than twice as great as the costs of the intervention [28]. A
similar program implemented in another upstate New York
MCO during the same time period reported investment costs
(including provider reimbursements) of $573,355, cost sav-
ings of $789,621 resulting from the estimated prevention
of 48 LBW births, and a net benefit of $216,266 [27]. The
authors reported an internal rate of return of 37% on the
investment, which is equivalent to an ROI ratio of 1.37.
Economic analyses of preconception care
Finally, we turn to the application of business case methods to
preconception care. Preconception care refers to three types
of services and target populations:
 Preventive services and screenings offered to women who
expect to become pregnant in the near future;
 Interconception care for women who have given birth and
intend to bear another child at some point in the future;
 Counseling about the impact of pre-existing health risks
or conditions for affected women of childbearing age and
their impact on pregnancy outcomes.
Few economic evaluations of individual screenings or ser-
vices in the pre-pregnancy period have been published. One
CEA estimated that promoting folic acid supplementation to
all women of reproductive age would be cost effective, al-
though not cost saving [30]. If multivitamins containing folic
acid were targeted instead to women intending pregnancy,
supplementation might be cost saving. On the other hand,
because most of the averted costs of caring for children with
spina bifida occur years in the future and are shared by mul-
tiple payers, this type of analysis cannot be used to calculate
the business case for folic acid supplementation strategies.
One preconception care service with published analyses
of short-term financial costs and benefits is preconception
counseling for women with diabetes. Women with poorly
controlled diabetes before pregnancy have an elevated risk
of having an infant with a birth defect [31], fetal death, or
macrosomia. Women with poorly controlled diabetes prior
to pregnancy can also experience medical risks during preg-
nancy, including diabetic retinopathy, nephropathy, and ke-
toacidosis, as well as pregnancy-induced hypertension and
uteroplacental insufficiency [32].
A substantial body of evidence on infant health outcomes
associated with preconception counseling for women with
diabetes yields consistent findings. According to a meta-
analysis of 14 epidemiologic studies, pregnancies preceded
by preconception care result in one third as many major con-
genital malformations as pregnancies not preceded by pre-
conception care [31]. The Maine Diabetes in Pregnancy Pro-
gram found 4-fold lower rates of both congenital anomalies
and fetal and neonatal deaths among pregnancies with pre-
conception care [33]. More recently, the Diabetes Complica-
tions Control Trial (DCCT) of 1441 adults with Type 1 dia-
betes randomly assigned to conventional or intensive therapy,
including 180 women who became pregnant, reported 8 con-
genital malformations in the conventional therapy group and
only 1 in the intensive therapy group [34]. Thus, in the case of
maternal diabetes, randomized trial data confirm the findings
of numerous observational studies that control of diabetes
prior to pregnancy results in dramatically fewer birth defects.
Three economic evaluations of preconception and preg-
nancy care programs for women with non-gestational di-
abetes were identified in the published literature [35–37].
All reported calculations of net short-term economic benefit
based on reduced costs of maternal and neonatal hospitaliza-
tions and did not take into account long-term averted costs of
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care associated with the prevention of birth defects. Although
the analyses were not developed as business case analyses,
the focus on short-term costs and benefits is consistent with
that approach. Regrettably, the lack of common metrics of
cost and health outcomes makes it difficult to make direct
comparisons of assumptions and findings of the three studies.
The first study is a prospective analysis of a hypotheti-
cal program of comprehensive preconception diabetes care
consisting of 20 visits prior to prenatal care [35]. The precon-
ception visits were projected to cost $2,638 per enrollee in
1989 dollars. The investigators calculated that reduced ma-
ternal and infant hospitalizations would result in net benefits
of $1,720 per enrollee. The majority of the hospitalization
cost savings were projected to result from an 8-fold reduc-
tion in major congenital malformations, from 3.2 to 0.4%.
Using the cost of the intervention as the denominator, the
benefit-cost ratio from the health care system perspective
can be calculated to be 1.6. This means that, on average,
for every $1 spent on the program, reduced hospitalization
costs of $1.60 would be expected. Although the projected
percentage reduction in major malformations appears high
relative to the literature, the projected intervention cost was
also rather high, since it is uncertain that 20 visits would be
needed for preconception care for women with diabetes.
The second study, a retrospective analysis of data for the
years 1986–1988 from the California Diabetes and Preg-
nancy Program (CDAPP), found that matched perinatal hos-
pital charges for mother and child were 41% higher for con-
trols than for program participants [36]. The benefit-cost ratio
was 5.19, with reduced maternal and infant hospitalization
costs of $5.19 observed for each $1 spent on the program.
This finding likely contributed to the ongoing funding of the
CDAPP. It is difficult to apply these findings to preconcep-
tion care, though. Only 24 of 102 participants were enrolled
in the program prior to 8 weeks of gestation, the time during
which major congenital malformations are likely to occur.
Although those participants had average charges that were
44% lower than those who enrolled after 8 weeks, women
who enrolled in the program prior to conception incurred
higher costs per delivery because of the longer time during
which services were received and the fact that not all women
who enrolled became pregnant. Therefore, positive net fi-
nancial returns to the component of preconception care were
not demonstrated in that study.
The third study is a retrospective evaluation of prospec-
tively gathered data on pregnancy-related costs among
women with type 1 diabetes who received both preconcep-
tion care and prenatal care or prenatal care only at selected
Michigan hospitals [37]. Women in the preconception care
group received an additional two outpatient visits on average,
at an added cost of $132. The rate of congenital malforma-
tion was 4.2% in the preconception care group compared
with 13.5% in the prenatal care-only group, a reduction of
69%. The rate of maternal and neonatal intensive care unit
(NICU) hospitalizations was 50% lower in the preconception
care group. Combining maternal and child hospitalizations,
cost savings averaged $34,000 per woman enrolled in both
preconception and prenatal care compared to those who re-
ceived standard prenatal care. Although no information was
presented on the distribution of costs in this study, an impli-
cation of the findings is that an integrated health plan could
likely achieve cost savings by paying for a modest number
of preconception care visits for women with type 1 diabetes.
Discussion
The economic and business case literature on preconception
care is quite limited. There is some evidence of positive fi-
nancial returns for preconception counseling for women with
diabetes, based on savings in hospitalization costs [35–37].
Although none of the studies involved randomized assign-
ment, the relative differences in frequencies of birth defects
are consistent with findings from other studies and increase
the confidence that can be placed in the estimates of cost
reductions. None of the studies indicate who was expected
to bear the costs of counseling or the magnitude of cost sav-
ings to specific stakeholders. The studies are all based on
relatively old data; newer studies with more complete ac-
counting of costs would be more informative. Furthermore,
determination of the optimal number and cost of preconcep-
tion visits is essential.
The American Diabetes Association [38] and the Amer-
ican College of Obstetricians and Gynecologists [39] rec-
ommend that all women of childbearing age with diabetes
receive counseling about the importance of glucose control
before becoming pregnant. Despite these guidelines and pos-
itive economic analyses, many women with diabetes still do
not receive such advice. A recent survey of women with di-
abetes ages 18 to 45 years enrolled in managed care plans
found that only about half recalled receiving advice about the
need for glucose control prior to pregnancy [40]. Research
is needed to determine why some women with diabetes seek
out preconception care and adopt intensive glucose control
measures and others do not [41]. Potential barriers, such as
opportunity cost of time, financial cost (e.g., co-pays), in-
vasive testing, and medical risks [32] need to be analyzed
from the consumer perspective. For example, it has been es-
timated that for patients with type 2 diabetes controlled by
oral agents, following all self-care practices recommended
by the American Diabetes Association could require more
than 2 hours daily [42].
Better data are needed to establish the business case for
preconception care. Although benefits of preconception care
can be projected, data derived from the evaluation of ac-
tual preconception care initiatives are needed to make a
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compelling business case. Further, observational data com-
paring pregnancy outcomes among women who choose to
use preconception care and those who do not are subject
to biases due to non-randomized study design. A business
case analysis of interventions with both demonstrated effi-
cacy (works if followed) and effectiveness (behaviors are
actually changed and lead to improved outcomes) is likely to
be more persuasive. In order to develop a compelling busi-
ness case for preconception care, studies of preconception
care interventions accompanied by rigorous evaluations with
randomized or matched groups of controls are required.
Preparing a business case analysis based on intervention
data poses challenges. It is logistically difficult but essen-
tial to prospectively collect data on costs and outcomes: “To
understand which quality-enhancing interventions are likely
to produce positive returns on investments, data collection
and analysis must include tracking the investment and oper-
ating costs of implementing the intervention as well as the
changes in revenues and costs that result from the interven-
tion” [24]. Easily accessible or extant data sets typically do
not allow one to calculate costs from the perspective of an
individual organization. This requires quantifying actual re-
imbursements, co-pays, deductibles, etc., rather than using
standard charges for a clinic visit. It also requires tracking
which patients are covered by different health plans and pat-
terns of enrollment and disenrollment.
Conclusion and the way forward
Research demonstrating the effectiveness and financial re-
turns to investments in preconception care is necessary to
make a financial business case for preconception care. In
particular, the only economic evaluations that have been
published to date have been of specific components of pre-
conception care, such as counseling women with diabetes
or promoting preconception use of folic acid supplements.
Evaluations of the costs and benefits of different “bundles”
of preconception care services or comprehensive preconcep-
tion care are needed. Further, such evaluations must include
payer-specific cost data to be relevant to framing the business
case for preconception care.
Although more data are needed, such analyses may not
be sufficient to ensure access to or provision of preconcep-
tion care, as the diabetes preconception care experience sug-
gests. Promotion of preconception care through carefully
researched health marketing campaigns is also critical [41].
If, as a result of effective health marketing, consumers were
to demand preconception care, providers and payers would
be more likely to perceive a business case for providing it.
Similarly, a business case might also be supported if health
care professionals working with women of childbearing age
were to advocate that their own organizations provide such
services. Health care providers often lack the incentive to
adopt a new service that improves outcomes; therefore, par-
ticular attention must be paid to the structure of incentives
by both public and private payers and purchasers [3].
Public health programs should fund studies evaluating the
effectiveness of preconception care and develop marketing
strategies to promote awareness of strategies that are proven
effective. Studies that test and evaluate preconception care
strategies should collect the financial data needed to conduct
business case analyses [24]. Controlled evaluations of pre-
conception care need to be accompanied by financial analy-
ses to help make the business case for providing and paying
for such services. Better quality evidence of both the financial
and health costs of poor pregnancy outcomes and the bene-
fits from preconception and early prenatal care is needed to
provide a compelling business case.
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